Efficacy and Safety of Pitavastatin in a Real-world Setting

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

28343 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-04-02

Study Completion Date

2017-08-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The prospective, observational, non-comparative trial in South Korea was designed to evaluate the efficacy and safety of pitavastatin (Livalo) in clinical practice in 28,343 patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Efficacy Study of Pitavastatin in Patient With a Metabolic Syndrome

NCT00640276

Hypercholesterolemia Metabolic Syndrome

COMPLETED PHASE4

A Study to Evaluate the Efficacy and Safety of Fixed-Dose Combination of Pitavastatin/Ezetimib

NCT06314919

Primary Hypercholesterolemia Mixed Dyslipidemia

RECRUITING

Effect of Pitavastatin on Coronary Flow Reserve in Hypertensive Patients

NCT02144922

Hypertension Cardiovascular Risk

COMPLETED PHASE4

Effect of High-dose Pitavastatin on Glucose Control in Patients With Metabolic Syndrome

NCT02940366

Metabolic Syndrome

UNKNOWN PHASE4

Livalo Acute Myocardial Infarction Study

NCT00805714

Acute Myocardial Infarction

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study was conducted in 893 facilities in Korea from 2 Apr 2012 to 1 Apr 2017. This study was designed to administer 1mg, 2mg, or 4mg pitavastatin to patients with hyperlipidemia at the age of 20 or older for at least 8 weeks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypercholesterolemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pitavastatin

1mg, 2mg, or 4mg, Once a day, at least 8 weeks

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

LIVALO

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients in need of statin treatment who are taking or are planning to take Livalo tablets, or who are taking other statins or are planning to change to Livalo tablets.

Exclusion Criteria

* Patients with hypersensitivity to pitavastatin
* Patients with active liver disease or untranslated transaminase levels Patients with a constant rise in
* Patients with severe liver failure or biliary obstruction and patients with cholestasis
* Patients who are receiving cyclosporine
* Myopathy patients
* Pregnant women or women of childbearing age and lactating women
* Children
* Patients with genetic problems, such as galactose intolerance, Lapp lactose deficiency or glucose-galactose
* Patients deemed inappropriate by the investigator

Eligible Sex

ALL

Accepts Healthy Volunteers

No